SPEAKER SCHEDULE

,

JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000397292.87679.2b
Speaker Schedule
    Back to Top | Article Outline

    SPEAKER SCHEDULE*

    Monday, October 4, 2010

    10:30 a.m. Satellite Symposium

    Back to Top | Article Outline
    Fogarty Scholars Forum

    Chair: William A. Blattner, M.D. - Institute of Human Virology

    Back to Top | Article Outline
    Italian Society for Medical Virology (SIVIM) Symposium

    Back to Top | Article Outline
    HIV in Italy

    Chairs: Maria C. Re, Ph.D. - University of Bologna andAdriano Lazzarin, M.D. - Università Vita-Salute San

    Raffaele

    1:00 p.m. Introduction: Giuseppe Ippolito, M.D., Scientific director - National Institute for Infectious diseases

    HIV/AIDS in Italy: Divers and Dynamics

    1:05 p.m. Paola Cinque, M.D. - San Raffaele Scientific Institute

    Immunoactivation and HIV

    1:23 p.m. Gabriella D'Ettorre, M.D. - La Sapienza University 102

    HIV-DNA and Therapy

    1:41 p.m.  Filippo Canducci, M.D. - Vita-Salute San Raffaele University

    Viral Fitness and Therapy of HIV Infection

    2:00 p.m. Mauro Pistello, Ph.D. - University of Pisa

    Lessons Learned from the Feline Immunodeficiency Virus/AIDS Model

    Back to Top | Article Outline
    Special Symposium on HIV and Malignant Disease in Africa

    Chairs: Mauro Moroni, M.D. - Ospedale Niguarda Ca' Granda, Umberto Tirelli, M.D. - National Cancer Institute and Joe O'Neill - University of Maryland, Baltimore

    2:18 p.m. William Blattner, M.D. - Institute of Human Virology 105

    HIV and Viral Associated Malignancies

    2:36 p.m.  Clement Adebamowo, D.Sc., M.D., FWACS, FACS - Institute of Human Virology 106

    Cancer Research in Africa

    2:54 p.m. Annie Sasco, M.D., Ph.D. - Victor Ségalen Bordeaux 2 University 107

    Cancer and HIV in Sub-Saharan Africa: Not Exactly as in the North

    3:12 p.m. Max Essex, DVM, Ph.D. - Harvard University School of Public Health 108

    HIV-1C of Southern Africa: Why is the Virus More Fit?

    3:30 p.m. Sam Mbulaiteye, M.D. - National Cancer Institute 109

    Epidemiology of AIDS-Related Malignancies: Current Knowledge and Opportunities for Etiological Studies in the Setting of HIV Treatment Programs

    Back to Top | Article Outline
    Roundtable: Research Needs and Challenges in Africa and the Developing World

    Moderator: Joe O'Neill, M.D - University of Maryland, Baltimore

    William Blattner, M.D. - Institute of Human Virology, Clement Adebamowo, D.Sc., M.D., FWACS, FACS

    - Institute of Human Virology, Annie Sasco, M.D., Ph.D. - Victor Ségalen Bordeaux 2 University, Max

    Essex, DVM, Ph.D. - Harvard University School of Public Health, Sam Mbulaiteye, M.D. - National Cancer

    Institute

    4:00 p.m. ADJOURN

    Back to Top | Article Outline

    Formal Opening Ceremony, Welcome and Reception

    6:00 p.m. Refreshments

    6:30 p.m. Welcome Remarks by Robert C. Gallo

     Kathleen kennedy Townsend, Chair IHV Board of Advisors

     Ferruccio fazio, Minister of Health

     Giuseppe Scopelliti, Governor of Calabria

     Giovanni Latorre, Ph.D, Rector - University of Calabria

    7:00 p.m. Robert C. Gallo, M.D. - Institute of Human Virology Key Problems in HIV Research

    7:15 p.m. Light Dinner: Speakers, participants, and guests are invited to attend.

    Back to Top | Article Outline
    Tuesday, October 5, 2010
    Insights from Basic Science 1

    Chairs: Giuseppe Teti, M.D. - University of Messina Medical School and Roberto Accolla, M.D. - University of

    Insubria

    9:00 a.m.Andrea Cerutti, M.D. - Weill Cornell Medical College 110

    Nef-Trafficking Intercellular Highways for HIV Evasion of Antibody Production

    9:18 a.m.Suzanne Gartner, Ph.D. - Institute of Human Virology 111

    Generation of Cells Within Human Nurse Macrophages and Consequences Following HIV Infectio

    9:36 a.m.Guido Poli, M.D. - San Raffaele Scientific Institute 112

    Multifaceted Infection and Replication ofHIV-1 in Human Macrophages

    9:54 a.m.  Warner Greene, M.D., Ph.D. - Gladstone Institute of Virology and Immunology  113

    Murder on the HIV Express: Insights into How CD4 T Cells are Killed in Lymphoid Tissues

    10:12 a.m. Leonid Margolis, Ph.D. - National Institutes of Health 114

    HIV Interactions With Other Viruses in Human Tissues as Determinants of HIV Infection

    10:30 a.m. William Hall, M.D., Ph.D. - University College dublin 115

    HIV-1 Rev and Regulation of Rev Nucleo-Cytoplasmic Shuttling

    20 minutes BREAK

    Back to Top | Article Outline
    Special Lecture

    10:47 a.m. Zeng Yi, Ph.D. - Institute for Viral disease

    Prevention and Control Study on Therapeutic Vaccine for AIDS Treatment

    Back to Top | Article Outline
    Insights from Basic Science 2

    Chairs: Umberto Bertazzoni, Ph.D. - University of Verona and Vittorio Colizzi, M.D., Ph.D. - University of

    Rome, Tor Vergata

    11:10 a.m. John Moore, Ph.D. - Weill Cornell Medical College 118

    Inhibiting CCR5 in vitro and in vivo

    11:28 a.m. Mario Stevenson, Ph.D. - University of Massachusetts Medical Center 119

    Viral Attack and Cellular Defense: The Role of Cellular Restrictions in the Biology of Primate Lentiviruses

    11:46 a.m. Alain Lafeuillade, M.D. - Chalucet Hospital 120

    HIV Persistence Challenging Therapeutic Success

    12:04 p.m. Marie-Lise Gougeon, Ph.D. - Institute Pasteur 121

    Contributions of Innate Immunity to the Establishment of HIV Reservoir in DC: Role for DC:NK Cross-Talk

    12:22 p.m. Monsef Benkirane, Ph.D. - Institute of Human Genetics 122

    Interplay Between HIV Replication and MicroRNAs

    12:40 p.m. Eric Verdin, M.D. - Gladstone Institute of Virology and Immunology 123

    Molecular Mechanisms of HIV Latency

    12:58 p.m.  LUNCH

    2:30 p.m.  Institute of Human Virology Lifetime Scientific Achievement Award 2010

     Robert C. Gallo, M.D. - Institute of Human Virology

    Introduction ofRino Rappuoli, Ph.D., 2010 Award Recipient

    Back to Top | Article Outline
    Special Seminar

     Rino Rappuoli, Ph.D.

    Novartis Vaccines and Diagnostics

    3:00 p.m.  Selected Abstracts for Oral Presentation

    Chairs: Fernando Aiuti, M.D. - University of Rome and Nancy Miller, M.D. - National Institute of Allergy and

    Infectious Diseases

    3:05 p.m. Alfredo Garzino-demo, Ph.D. - Institute of Human Virology 124

    CCR6 Ligands Inhibit HIV in Highly Susceptible CD4+CCR6+ T Cells by Inducing APOBEC3G Expression

    3:12 p.m. Giulia della Chiara, Ph.D. - San Raffaele Scientific Institute 125

    Naturally c-Terminally Truncated STAT5 (STAT5Δ): A Negative Controller of HIV-1 Transcription and Expression

    3:19 p.m. Marina Lusic, Ph.D. - San Raffaele Scientific Institute 126

    PML Nuclear Bodies Determine the Repressive Environment and Restrict Viral Gene Expression in Primary Human Lymphocytes

    3:26 p.m. Elisa Vicenzi - San Raffaele Scientific Institute 127

    Characterization of Tripartite-Motif (TRIM) 22-Mediated Inhibition ofHIV-1 Transcription

    3:33 p.m. Olga Latinovic, Ph.D. - Institute of Human Virology 128

    Suppression of CCR5 Density as a Novel Way to Enhance the Anti-HIV Activity of Fusion Inhibitors and CCR5 Antagonists

    3:40 p.m. Apostolos Rizos, Ph.D. - University of Crete 129

    HIV and Immune System Deregulation

    3:47 p.m. Ming Zeng, Ph.D. - University of Minnesota 130

    Lymphoid Tissue Niche Damage in SIV Infection Depletes Naïve T Cells

    3:54 p.m. A.J. Smith, Ph.D. - University of Minnesota 131

    The Role of Chitinase 3-Like-1 in the Pathological Deposition of Collagen in Lymphatic Tissue During HIV-1Infection

    4:01 p.m. Michael Thomson, Ph.D. - Institute de Salud Carlos III 132

    Identification of New Patterns of Splice Site Usage by Transcripts of HIV-1 Primary Isolates of Diverse Subtypes

    4:08 p.m. Ramesh Akkina, Ph.D. - Colorado State University 133

    Aptamer-siRNA Chimera Therapy Suppresses HIV-1 Viral Loads and Protects From CD4 TCell Loss in Humanized (RAG-hu) Mice

    4:15 p.m. Cristiana Cairo, Ph.D. - Institute of Human Virology 134

    Population Level Variations in the Baseline Value for Vδ2 T Cells and Implications for the Study of Infectious Diseases

    4:22 p.m.  Natalia freund, Ph.D. - Tel Aviv University 135

    Reconstitution of Conformational B-Cell Epitopes Using Combinatorial Con former Libraries

    4:29 p.m.  Chiara Orlandi, Ph.D. - University of Insubria 136

    HTLV-2 Tax-2 Transactivator Increases the Expression and the Function of its Inhibitor CIITA, the Master Regulator of HLA-II Gene Transcription

    4:36 p.m. ADJOURN

    6:00 p.m. Aperitivo

    8:30 p.m.  Lifetime Achievement Gala Banquet and Awards Ceremony

    Location: Sunshine Club Hotel Ballroom

    All speakers, participants, and guests are invited to attend.

    Back to Top | Article Outline
    Wednesday, October 6, 2010
    HIV Vaccine Part 1: Challenges to HIV Vaccine Development

    Chairs: Robert C. Gallo, M.D - Institute of Human Virology and Franco Buonaguro, M.D - National Cancer

    Institute, Fond Pascale

    9:00 a.m.  Robert C. Gallo, M.D. - Institute of Human Virology

    Introduction - The Key Basic Science Issues in Developing an HIV Vaccine

    9:18 a.m.  Nelson L. Michael, M.D., Ph.D. - Walter Reed Army Institute of Research 138

    Building on the Results of the RV144 Prime Boost HIV Vaccine Efficacy Study

    9:36 a.m.  Jay Berz of sky, M.D., Ph.D. - National Cancer Institute 139

    A Novel Nanoparticle Approach to Induce Colorectal and Vaginal Mucosal Immunity

    9:54 a.m.  Mark J. Newman, Ph.D.-GeoVax Inc. 140

    Induction of Efficacious Immune Responses Using Heterologous Prime Boost Regimens of Recombinant DNA and MVA HIV Vaccines and GM-CSF as the Adjuvant

    Back to Top | Article Outline
    HIV Vaccine Part 2: Antibody Response to HIV Env

    Chairs: Alan Bernstein, OC, Ph.D., FRSC - Global HIV Vaccine Enterprise and Massimo Clementi, M.D.

    - Università Vita-Salute San Raffaele

    10:12 a.m.  Leonidas Stamatatos, Ph.D. - Seattle Biomedical Research Institute 141

    Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1

    10:50 a.m. Jonathan Gershoni, Ph.D. - Tel Aviv University 142

    Steps Toward Epitope-Based Vaccines

    11:08 a.m. Julie Overbaugh, Ph.D. - fred Hutchinson Cancer Research Center 143

    HIV Transmission: The Role of Neutralizing Antibodies

    11:26 a.m. Anthony DeVico, Ph.D. - Institute of Human Virology 144

    Protection Against Heterologous SHIV Challenge Afforded by Immunization of Rhesus Macaques With a Subunit Immunogen that Mimics a Transition State HIV Envelope Structure

    Back to Top | Article Outline
    Special Lecture

    11:44 a.m.  Hans Wigzell, M.D., director of the Center for Medical Innovations -Karolinska Institute

    12:02 p.m. Roundtable: What Has Been Learned from Clinical Trials

    Moderator: Alan Bernstein, OC, Ph.D., FRSC - Global HIV Vaccine Enterprise

    Gary Nabel, M.D., Ph.D. - National Institutes of Health; Nelson L. Michael, M.D., Ph.D. - Walter Reed Army

    Institute of Research; Robert C. Gallo, M.D. - Institute of Human Virology; Jim Tartaglia, Ph.D. - Sanofi

    Pasteur, Ltd.; Hans Wigzell, M.D., Director of the Center for Medical Innovations - Karolinska Institute; and

    David Montefiori, Ph.D. - Duke University

    Back to Top | Article Outline
    HIV Vaccine Part 3: Alternatives for Vaccine Delivery

    Chairs: Giorgio Palú, M.D. - University of Padua and Carlo F. Perno, M.D. - University of Rome Tor Vergata

    12:30 p.m. Gunnel Biberfeld, M.D., Ph.D. - karolinska Institutet 146

    Strong and Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Prime MVA Boost Vaccine Regimen Among Healthy Tanzanian Volunteers

    12:48 p.m.  Gary Nabel, M.D., Ph.D. - National Institutes of Health 147

    Rational Design of Envelope Surface Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

    1:06 p.m. Jim Tartaglia, Ph.D. - Sanofi Pasteur, Ltd. 148

    Moving Forward From RV144: An Industrial Perspective

    1:30 p.m.  LUNCH

    3:00 p.m. Dan Barouch, M.D., Ph.D. - Beth Israel deaconess Medical Center 149

    Novel Vectors and Antigens for a Next Generation HIV-1 Vaccine

    3:18 p.m. Genoveffa Franchini, Ph.D. - National Cancer Institute 150

    Retooling the Macaque Model as a Necessary Step to Evaluate the Relative Efficacy of Vaccines for HIV

    3:36 p.m. Giuseppe Pantaleo, M.D. - Centre Hospitalier Universitaire Vaudois 151

    Role of Poxvirus Vectors in the Development of an HIV Vaccine

    3:54 p.m.  Selected Abstracts for Oral Presentation

    Chairs: Michele La Placa, M.D. - University of Bologna and David Pauza - Institute of Human Virology

    4:00 p.m. Roberto f Speck, Ph.D. - University Hospital of Zurich 152

    TLR8 Triggering Induces HIV from Latently Infected Cells of Myeloid Monocytic Origin and Indirectly from Latently Infected CD4+ T Cells Via the MAPK Pathway and TNF-α Respectively

    4:07 p.m. Fabio Romerio, Ph.D. - Institute of Human Virology 153

    Modeling HIV-1 Latency in vitro

    4:14 p.m. Massimiliano Secchi, Ph.D. - San Raffaele Scientific Institute 154

    Anti-HIV-1 RANTES Derivatives Acting as CCR5 Antagonists Present Full Additivity or Synergy in Combination With Different Entry/Fusion Inhibitors

    4:21 p.m. Elisa Saba, Ph.D. - San Raffaele Scientific Institute 155

    HIV-1 Infection and Replication of Cervico-VaginalHistocultures

    4:28 p.m.  Laurel Lagenaur, Ph.D. - National Cancer Institute 156

    A Live Microbicide Shows Efficacy in a Repeated Low Dose Challenge Model

    4:35 p.m. Donato Zipeto, Ph.D. - University of Verona 157

    Fusion Complexes and CD-4 Independent Env for the Induction of Broad Spectrum Neutralizing Antibodies Against HIV-1

    4:40 p.m.  ADJOURN

    6:00 p.m. Aperitivo

    8:30 p.m.  Historical Lecture with Regional Dance Performance

     (Coordinated by Arnaldo Caruso and Sebastiano Ando)

    Location: Sunshine Club Hotel Ballroom

    Speakers, participants, and guests are invited to attend.

    Back to Top | Article Outline
    Thursday, October 7, 2010
    HIV Vaccine Part 4: Therapeutic Vaccines for HIV and Cancer

    Chairs: Cornel Fraefel, Ph.D. - ATH University of Zurich and Giampiero Carosi, M.D. - University of Brescia

    9:00 a.m. Arnaldo Caruso, M.D. - University of Brescia 158

    HIV-1 Matrix Protein p17:A Candidate Antigen for Therapeutic Vaccines Against AIDS

    9:18 a.m. Luigi Buonaguro, M. D. - Istituto Nazionale Tumori 159

    Immune Signatures and Systems Biology of Vaccines

    9:36 a.m. Jeffrey Schlom, Ph.D. - National Cancer Institute 160

    Recombinant Vector-based Vaccines for Cancer Therapy

     Zwi Berneman, MD, Ph.D. - Antwerp University Hospital 161

    Dentritic Cell Vaccination in Acute Myeloid Leukemia

    9:54 a.m.  Daniel Zagury, M.D. - NEOVACS 162

    Active Anti-IFN α Immnotherapy Applied to Chronic Viral and Autoimmune Diseases

    Back to Top | Article Outline
    HIV Vaccine Part 5: Defining Targets for Protective Immunity

    Chairs: Nelson L. Michael, M.D., Ph.D. - Walter Reed Army Institute of Research and Maria C. Re, Ph.D.

    - University of Bologna

    10:12 a.m.  Lucia Lopalco, Ph.D. - fondazione San Raffaele del Monte Tabor 163

    New Immune Strategies to Reduce CCR5 Expression and Block HIV Infection

    10:30 a.m.  Susan B. Zolla-Pazner, Ph.D. - NYU School of Medicine, Veterans Affairs Medical Center 164

    Using Epitopes Recognized by Monoclonal Antibodies as Vaccine Templates

    20 minutes BREAK

    10:50 a.m.  Ben Berkhout, Ph.D. - University of Amsterdam 165

    Reconsidering a Live-Attenuated HIV Vaccine?

    11:08 a.m.  George Lewis, Ph.D. - Institute of Human Virology 166

    Fc-Mediated Anti-HIV Effector Function Mediated by New Monoclonal Antibodies That Recognize Epitopes Selectively Exposed During Viral Entry

    11:26 a.m.  David Montefiori, Ph.D. - duke University Medical Cente 167r

    Magnitude and Breadth of the Neutralizing Antibody Response in RV144

    Back to Top | Article Outline
    HIV Vaccine Part 6: Lessons from Animal Models

    Chairs: Maria Salvato, Ph.D. - Institute of Human Virology and Massimo Galli, M.D. - University of Milan

    11:44 a.m. Anna Aldovini, M.D. - Children's Hospital Boston

    SIVDNA/rMVA Nasal Vaccination Provides Better Control of Viremia and Disease Progression in Female than Male Macaques

    12:02 p.m. Guido Silvestri, M.D. - University of Pennsylvania 169

    SIV Infection of Natural Hosts

    12:20 p.m.  Ruth Ruprecht, M.D., Ph.D. - Dana-Farber Cancer Institute

    Recombinant Protein Immunogens: Protection Against R5 Clade C SHIV Transmission and Correlates of Protection

    12:38 p.m. Christopher Miller, DVM, Ph.D. - California National Primate Research Center A Protective Live-attenuated AIDS Vaccine Suppresses Innate Immunity and Inflammation in Immunized Rhesus Macaques

    Back to Top | Article Outline
    HIV Clinical Science and Therapy

    Chairs: Gioacchino Angarano, M.D. - University of Bari and Robert Redfield, M.D. - Institute of Human Virology

    12:56 p.m. Introduction - Stefano Vella, M.D. - Istituto Superiore di Sanità

    1:00 p.m. MarkWainberg, Ph.D.-McGill AIdS Centre 172

    Monitoring HIV Drug Resistance as a Guide to Understanding Viral Pathogenesis

    1:15 p.m. Giuseppe Tambussi, M.D. - San Raffaele Scientific Institute

    Cytokine-based Therapy in HIV Infection: from IL-2 to IL-7

    1:30 p.m.  LUNCH

    3:00 p.m.  Antonella Castagna, M.D. - San Raffaele Hospital 174

    Salvage Therapy in HIV-1Infected Patients

    3:15 p.m. James Mullins, Ph.D.-University of Washington 175

    HIV-1 Evolution in Primary Infection is Affected by Stochastic Followed by Selective Processes

    3:30 p.m. Carl June, M.D. - University of Pennsylvania School of Medicine 176

    Exploring the Potential of CCR5 and CXCR4 Modified CD4 T Cells to Target the HIV-1 Reservoir

    3:45 p.m.  BREAK

    Back to Top | Article Outline
    New Treatment Approaches to HIV Disease

    Chairs: Roger Pomerantz, M.D. - Merck and Anita De Rossi, Ph.D. - University of Padua

    4:00 p.m. Introduction: Roger Pomerantz, M.D. - Merck Is a Cure Possible for HIV Disease?

    4:15 p.m. Anders Vahlne, M.D., Ph.D. - Karolinska Institutet 177

    Peptide Linkers Between Natural Antibodies and HIV Targets

    4:30 p.m. Robert Redfield, M.D. - Institute of Human Virology 178

    Targeting Cell Cycle to Enhance the Potency of Antiretroviral Therapeutic Agents

    4:45 p.m. Saverio Parisi, M.D. - University of Padua

    Residual Viremia and HIV Compartmentalization in HAART Treated Patients

    5:00 p.m. ADJOURN

    Scintille Fashion Show - by invitation only

    Back to Top | Article Outline
    Friday, October 8, 2010
    Some Infectious Causes or Possible Causes of Cancer

    Chairs: Robert C. Gallo, M.D. - Institute of Human Virology and Kiyoshi Takatsuki, M.D., Ph.D. - Kumamoto

    University School of Medicine

    9:00 a.m.  Kiyoshi Takatsuki, M.D., Ph.D. - kumamoto University School of Medicine 180

    Adult T-Cell Leukemia/Lymphoma in Japan: Reminiscences and Perspectives

    9:18 a.m.  Kuan-Teh Jeang, M.D., Ph.D. - National Institutes of Health 181

    HTLV-1 Research After Three Decades: Insights into Cellular Transformation Mechanisms for ATL (Adult T-Cell Leukemia)

    9:36 a.m. Toshiki Watanabe, M.D., Ph.D. - University of Tokyo 182

    Risk Indicators for Disease Progression in Asymptomatic HTLV-1 Carriers: A Nationwide Prospective Study in Japan and Expression Profile Analysis Based on the Material Bank

    9:54 a.m.  Mark Kaplan, M.D.-University of Michigan Medical Center 183

    HIV Exposes Major “Trafficking” in HERV-KHML-2 Viruses Which are Critical to the Pathogenesis of HIV Infection and Lymphoma

    10:12 a.m.  Reinhard kurth, Ph.D. - Robert koch Institute 184

    Beneficial and Detrimental Effects of Human Endogenous Retroviruses (HERVs)

    10:30 a.m.  David Markovitz, M.D. - University of Michigan 185

    Do Modern Endogenous Retroviruses Still Replicate?

    20 minutes BREAK

    Back to Top | Article Outline
    HIV-Associated Cancers

    Chairs: Marvin Reitz, Ph.D. - Institute of Human Virology and Eva Klein, M.D. - Karolinska Institutet

    11:10 a.m.  George klein, M.D., Ph.D. - karolinska Institutet 186

    Awakening of Dormant Tumor Cells by Inflammation

    11:28 a.m.  Dario Di Luca, M.D. - University of ferrara 187

    KSHV, Angionesis and Kaposi Sarcoma

    11:46 a.m.  Parkash Gill, M.D. - University of Southern California 188

    VEGF-Notch-EphrinB2 Pathways in AIDS-Related Kaposi Sarcoma

    12:04 p.m. James Goedert, M.D. - National Cancer Institute 189

    HIVTropism and Decreased Risk of Breast Cancer

    Back to Top | Article Outline
    Tumor Growth and Inhibition

    Chairs: Luigi Chieco-Bianchi, M.D. - University of Padua and Sebastiano Andò, M.D - University of

    Calabria

    12:22 p.m. Wuyuan Lu, Ph.D. - Institute of Human Virology 190

    Novel Classes of p53 Activators for Cancer Therapy

    12:40 p.m. Eitan Yefenof, Ph.D. - The Hebrew University, Hadassah Medical School 191

    Sensitizing Hemopoietic Malignant Cells to Glucocorticoid Induced Apoptosis by PK Inhibitors

    1:00 p.m.  LUNCH

    2:30 p.m. Isaac Witz, Ph.D. - Tel Aviv University 192

    Cross-Talk with the Microenvironment: The Case of Melanoma Brain Metastasis

    2:48 p.m. Andrei kozlov, Ph.D. - St. Petersburg University 193

    The Possible Evolutionary Role of Tumors in the Origin of New Cell Types

    Back to Top | Article Outline
    Selected Abstracts for Oral Presentation

    Chairs: Guido Poli, M.D. - San Raffaele Scientific Institute and Mark Kaplan, M.D. - University of Michigan

    Medical Center

    3:06 p.m. Franco Buonaguro, M.D. - National Cancer Institute, Fond Pascale 194

    HPV-Related Cancers in HIV-Infected Subjects

    3:13 p.m. Sayed Abdelwahab, Ph.D. - Minia University 195

    Hepatitis C Virus-Specific Immune Response Among Egyptian Healthcare Workers at High Risk of Infection Without Viremia or Seroconversion

    3:20 p.m. Jean Carr, Ph.D. - Institute of Human Virology 196

    Newly Identified Circulating Recombinant Form Coming in Nigeria

    3:27 p.m. Judith Torimiro, Ph.D.-Chantal Biya International Reference Centre 197

    Population Level Drug Resistance in HIV Type 1 Protease and Reverse Transcriptase in Cameroon: 1995-2010 Review

    3:39 p.m. Badran Bassam, Ph.D. - Institut Jules Bordet, Universite Libre de Bruxelles 198

    Identification of a Human Natureal Regulatory T-Cell Micro-RNA Signature and Demonstration of the Major Role Played by miR-31, miR-21 and Valproate in Foxp3 Expression

    3:46 p.m. Marco Rusnati, Ph.D. - University of Brescia 199

    Role of Heparan Sulfate Proteoglycans in HIV-l Tat-Induced Transendothelial Migration of Lymphoid Cells

    4:00 p.m.  ADJOURN

    © 2011 Lippincott Williams & Wilkins, Inc.